On September 24, 2025, Akari Therapeutics, Plc (Nasdaq: AKTX) announced key preclinical data demonstrating the potential of its novel antibody‑drug conjugate (ADC) spliceosome‑modulating payload, PH1, for the treatment of tumors driven by alternative splicing, specifically the Androgen Receptor splice variant 7 (AR‑V7) in prostate cancer.
The data show that PH1 suppresses AR‑V7 expression in the 22Rv1 metastatic castration‑resistant prostate cancer model, while in the hormone‑sensitive LnCAP model it exhibited single‑agent activity and additive effects when combined with the androgen‑receptor pathway inhibitors enzalutamide (Xtandi) or apalutamide (Erleada). These findings suggest that PH1‑based ADCs could be used either alone or in combination to delay or prevent the emergence of AR‑V7‑driven resistance, a major unmet need in mCRPC.
CEO Abizer Gaslightwala said the results “support the rationale for Akari to develop a novel ADC with our PH1 spliceosome‑modulating payload targeting prostate cancer either alone or in partnership.” The company plans to present the data at an upcoming scientific conference and to test PH1 ADCs against additional prostate cancer targets, continuing its strategy of advancing the PH1 platform and its lead candidate AKTX‑101, a Trop2‑targeting ADC, toward clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.